Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators
about
Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patientsRisk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda.Lack of pharmacokinetic interaction between amdoxovir and reduced- and standard-dose zidovudine in HIV-1-infected individuals.Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics.Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavir.Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial.Lopinavir/Ritonavir pharmacokinetic profile: impact of sex and other covariates following a change from twice-daily to once-daily therapy.Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals.Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients.Evaluation of antiretroviral therapy results in Blantyre, Malawi.Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience.Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African womenPharmacokinetics of phase I nevirapine metabolites following a single dose and at steady state.Clinical pharmacokinetics of antiretroviral drugs in older persons.Development of an optimized dose for coformulation of zidovudine with drugs that select for the K65R mutation using a population pharmacokinetic and enzyme kinetic simulation model.Caring for women living with HIV: gaps in the evidence.Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART.Population pharmacokinetics study of recommended zidovudine doses in HIV-1-infected childrenComparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis.Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children.Clinical and genetic determinants of nevirapine plasma trough concentration.
P2860
Q24602072-C8E760B0-47C4-43A9-9E7D-B368F586BE94Q33459535-8036852D-A64C-4F1A-BB14-10F24FAE4589Q33676340-13153861-521E-4A4B-BFBC-02A653BDE11FQ34149022-C628D654-57C9-4790-B2D3-FD87AECB3AF6Q34677780-5B7EB8EE-0A4F-4830-8D7C-0ABB44C3E0C8Q34732899-F98B6221-ECC2-4F3F-8E39-D629E074A16AQ34776414-6F590E66-2599-4F7D-AF5F-A01B6A597ABBQ35804046-D1332F9F-EEEB-4904-844E-6BDE9195F15DQ35826691-AFAA45EF-6CBC-40BC-8E53-195358773F98Q35937624-A1B09627-5714-4434-9AD4-9AD035EAB4A9Q36276839-FFEDC2F2-F67D-4C76-92AE-1D33BE18F51FQ36422444-ADD47F42-ACD7-4B58-9B5C-81912D4AB1CBQ36785839-A16589A2-DA2D-4B28-8F0F-9657EC8681BDQ36905884-0D6C4E8C-FB30-41E8-8902-76C0404CF2EFQ36993425-C908BB06-69B2-4458-9CFA-A940245B2CCBQ37212049-234C03F4-96A9-4EDA-9DC8-B3C6EDC6A880Q37245017-D9911F36-D7AF-4E30-9FA3-3575D23CEFE8Q37263890-977F5C86-BC37-414E-9372-267D99EF8EA0Q37361810-FBC4F264-66A9-4119-9CF1-8430D49E5DCCQ37509532-2FED48A3-F33C-4F45-93AD-F582EF542BF3Q55263551-AA4E5FD4-C158-4EED-85B3-0BB8F6356842
P2860
Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Population pharmacokinetics of ...... oup Protocol 241 Investigators
@ast
Population pharmacokinetics of ...... oup Protocol 241 Investigators
@en
type
label
Population pharmacokinetics of ...... oup Protocol 241 Investigators
@ast
Population pharmacokinetics of ...... oup Protocol 241 Investigators
@en
prefLabel
Population pharmacokinetics of ...... oup Protocol 241 Investigators
@ast
Population pharmacokinetics of ...... oup Protocol 241 Investigators
@en
P2093
P2860
P356
P1476
Population pharmacokinetics of ...... oup Protocol 241 Investigators
@en
P2093
J P Sommadossi
L B Sheiner
M A Fischl
M D Hughes
M S Hirsch
R T D'Aquila
V A Johnson
P2860
P304
P356
10.1128/AAC.43.1.121
P407
P577
1999-01-01T00:00:00Z